Ocugen, Inc.
General ticker "OCGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $283.4M (TTM average)
Ocugen, Inc. follows the US Stock Market performance with the rate: 54.8%.
Estimated limits based on current volatility of 7.4%: low 1.67$, high 1.93$
Factors to consider:
- Total employees count: 84 as of 2022
- Top business risk factors: Lack of profitability, Product development risks, Manufacturing risks, Geopolitical risks, Regulatory and compliance
- Current price 105.1% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.41$, 1.44$]
- 2025-12-31 to 2026-12-31 estimated range: [0.22$, 0.82$]
Financial Metrics affecting the OCGN estimates:
- Positive: with PPE of -4.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.91 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: 19.35 < Shareholder equity ratio, % of 35.94 <= 42.53
- Negative: Investing cash flow per share per price, % of -1.60 <= -0.62
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term OCGN quotes
Long-term OCGN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.49MM | $6.04MM | $4.05MM |
| Operating Expenses | $91.56MM | $71.57MM | $58.81MM |
| Operating Income | $-89.07MM | $-65.53MM | $-54.76MM |
| Non-Operating Income | $2.27MM | $2.45MM | $0.70MM |
| R&D Expense | $56.16MM | $39.57MM | $32.13MM |
| Income(Loss) | $-86.80MM | $-63.08MM | $-54.05MM |
| Profit(Loss)* | $-86.80MM | $-63.08MM | $-54.05MM |
| Stockholders Equity | $73.98MM | $40.56MM | $29.63MM |
| Assets | $108.63MM | $64.55MM | $82.44MM |
| Operating Cash Flow | $-60.08MM | $-62.05MM | $-42.14MM |
| Capital expenditure | $4.46MM | $10.48MM | $3.38MM |
| Investing Cash Flow | $-16.97MM | $3.08MM | $-3.38MM |
| Financing Cash Flow | $59.48MM | $20.88MM | $64.86MM |
| Earnings Per Share** | $-0.40 | $-0.26 | $-0.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.